title: Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial.
abstract: OBJECTIVE
  Thiazolidinediones are insulin sensitizers, and are associated with fluid retention and increased risk of heart failure (HF) in people with type 2 diabetes. We assessed fatal and non-fatal HF events and their outcome, and identified HF predictors in the RECORD (Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of glycaemia in Diabetes) trial population.
  
  
  RESULTS
  In a multicentre, open-label study, we randomized 4447 people with type 2 diabetes on metformin or sulfonylurea monotherapy with a mean HbA(1c) of 7.9% to add-on rosiglitazone (n = 2220) or to a combination of metformin and sulfonylurea (n = 2227) and followed them over 5.5 years on average. Heart failure hospitalizations and deaths were adjudicated by a Clinical Endpoint Committee using pre-specified criteria. Independent predictors of HF events were identified out of a group of 30 pre-specified clinical, demographic, and biological variables. In the rosiglitazone group, the risk of HF death or hospitalization was doubled: HR = 2.10 (95% CI, 1.35-3.27): the excess HF event rate was 2.6 (1.1-4.1) per 1000 person-years. An excess in HF deaths was observed (10 vs. two), including four HF deaths as first HF events. By contrast, there was no increase in cardiovascular mortality or hospitalization (HR = 0.99, 95% CI, 0.85-1.16) or in cardiovascular deaths (60 vs. 71). Independent predictors of HF were rosiglitazone assignment, age, urinary albumin : creatinine ratio, body mass index, and systolic blood pressure at baseline. A history of previous cardiovascular disease was not predictive of HF. Duration of HF hospitalization and rate of HF re-hospitalization were similar in the two groups.
  
  
  CONCLUSIONS
  These findings confirm the increased risk of HF events in people treated with rosiglitazone and support the recommendation that this agent should not continue to be used in people developing symptomatic HF while using the medication. Close follow-up for the risk of HF should be offered to elderly people, people with markedly increased body mass index, people with microalbuminuria/proteinuria, and people with increased systolic blood pressure.
authors.affiliation: Université Pierre et Marie Curie Paris 6, Paris, France. michel.komajda@psl.aphp.fr
authors.forename: Michel
authors.initials: M
authors.lastname: Komajda
authors.forename: John J V
authors.initials: JJ
authors.lastname: McMurray
authors.forename: Henning
authors.initials: H
authors.lastname: Beck-Nielsen
authors.forename: Ramon
authors.initials: R
authors.lastname: Gomis
authors.forename: Markolf
authors.initials: M
authors.lastname: Hanefeld
authors.forename: Stuart J
authors.initials: SJ
authors.lastname: Pocock
authors.forename: Paula S
authors.initials: PS
authors.lastname: Curtis
authors.forename: Nigel P
authors.initials: NP
authors.lastname: Jones
authors.forename: Philip D
authors.initials: PD
authors.lastname: Home
mesh_terms: D000328:Adult; D000368:Aged; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000401:mortality; D005260:Female; D006333:Heart Failure / Q000139:chemically induced* / Q000401:mortality; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects*; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D012307:Risk Factors; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000009:adverse effects*
chemical_list: D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D000077154:Rosiglitazone